For a century, insulin therapy has kept people with Type 1 diabetes alive, but it has never fully replicated the second-by-second responsiveness of a healthy pancreas. Artificial Pancreas Device Systems (APDS) close that gap. By pairing continuous glucose monitoring with algorithm-driven insulin pumps, these systems automate a task that once demanded constant vigilance from patients and caregivers alike. What began as a narrow clinical niche has, over the past five years, evolved into one of the fastest-growing categories in connected medical devices, reshaping not only patient outcomes but also the competitive and commercial landscape of diabetes care.
What is an ...
